Detection and quantitation of circulating immune complexes in arterial blood of patients with rheumatic disease.

R. Panush,P. Katz,S. Longley,R. Yonker

DOI: https://doi.org/10.1016/0090-1229(85)90123-0

1985-07-01

Clinical Immunology and Immunopathology

Abstract:

What problem does this paper attempt to address?

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Xuefen Li,Yumiao Xu,Yuejiao Dong,Xianzhi Yang,Bo Ye,Yiyin Wang,Yu Chen

DOI: https://doi.org/10.1016/j.vaccine.2018.03.044

IF: 4.169

2018-01-01

Vaccine

Abstract:Vaccination against hepatitis B virus (HBV) is recommended worldwide. The aim of this study was to assess the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children in the context of protective anti-HBs levels and cellular immune responses. Using a random questionnaire survey, 1695 pre-school children were recruited as research subjects during January 2015 to June 2017. Blood samples were obtained to measure HBV serological markers as well as peripheral immunocytes. The children were divided into non-, low- and hyper- responsive groups (NR, LR, and HR) based on the vaccination efficacy. Additionally, the effect of revaccination on the NR group was evaluated at 1 month after completion of the vaccination course. Among a total of 1695 children, 1591 (93.86%) were infants who were followed while undergoing their primary course of hepatitis B vaccination at the 0-1-6 month schedule, and 1249 (79.30%) of them developed antibodies against HBsAg (anti-HBs) titers greater than 10 IU/L. The results of immunocyte studies indicated that the CD8+ T cells, CD4+CD45RO+ T cells, CD8+CD45RA+ T cells, and T follicular helper (Tfh) cells increased significantly in NR compared with HR. However, lymphocytes, CD4+ T cells, and CD4+CD45RA+ T cells in NR were lower than that in HR. 96 of the non-response cases showed seroprotection after revaccination among 103 cases. Therefore, most of the preschool children who received hepatitis B vaccine in infancy achieved significant seroprotection. Seroconversion rates of individuals revaccinated after initial vaccination failure were significantly higher than those after primary vaccination. Different vaccination efficacy groups showed significant changes in circulating immunocytes, which might be a factor affecting the recombinant HBV vaccine's immune effectiveness.
Efficacy of an accelerated double‐dose hepatitis B vaccine regimen in patients with cirrhosis

Sergio Rodríguez‐Tajes,Anna Pocurull,Sabela Lens,Zoe Mariño,Ignasi Olivas,Guillem Soy,Anna Alonso,Anna Vilella,Xavier Forns

DOI: https://doi.org/10.1111/jvh.13509

2021-04-01

Journal of Viral Hepatitis

Abstract:<p>The hepatitis B (HBV) vaccine is recommended in unvaccinated adults with cirrhosis, despite its low efficacy. We aimed to evaluate the response to a double dose/accelerated vaccine schedule in patients with cirrhosis admitted into a Hepatology ward. All patients with cirrhosis admitted to the hepatology ward without exclusion criteria were offered the HBV HBVAXPRO 40mcg vaccine at months 0, 1 and 2. Non‐responders received a second cycle.We evaluated 468 patients and only 19% were seroprotected against HBV. In 196 patients without exclusion criteria for HBV vaccination the per protocol response rate (anti‐HBs > 10 U/mL) was 23% after a first cycle and 59% after a second cycle. The overall response per intention to treat was only 23%. We have not identified predictors of response. Only one patient had a mild adverse event.Most patients with cirrhosis admitted in the Hepatology ward are unprotected against HBV. Although a second HBV vaccination cycle increases the response rate, the poor overall response reinforces the implementation of HBV vaccination before the development of cirrhosis.</p>

gastroenterology & hepatology,infectious diseases,virology
Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Yan Qiu,Jing-Jing Ren,Zi-Kang Wu,Ling-Zhi Shen,Huan Shan,Xue-Wei Dai,Jing Li,Ying Liu,Wen Ren,Jun Yao,Lan-Juan Li

DOI: https://doi.org/10.1080/21645515.2020.1738169

2020-01-01

Human Vaccines & Immunotherapeutics

Abstract:Debate continues regarding the need for a booster vaccination in children who received a universal infant hepatitis B virus (HBV) vaccination. The aim was to explore the need and the strategies for the booster HBV vaccination. 8-year prospective cohort study was conducted among children aged 5–15 years in 2009–2010 in Zhejiang Province. The participants were divided into groups A (<0.1 mIU/mL), B (0.1 to < 1 mIU/mL) and C (1 to <10 mIU/mL) according to the pre-booster anti-HBs antibody levels. 5 μg (group I), 10 μg (group II), 20 μg hepatitis B vaccines (group III) or 5 μg hepatitis A and B (HAB) vaccines (group IV) with 0-1-6-month schedule were randomly administered to children negative for all markers. Blood samples were collected at baseline HBV marker testing, 1 month after the first dose, 1 month, 1 year, 5 years and 8 years after the third dose. Among 4170 children, 2326 (55.8%) were negative for all HBV markers. Group II showed the highest seropositive rates of 92.8%, 99.7%, 97.6%, 90.3% and 83.4% with GMTs of 4194.5 mIU/ml, 4163.9 mIU/ml, 466.9 mIU/ml, 190.6 mIU/ml, 122.6 mIU/ml from 1 month after dose 1 to 8 years after dose 3, respectively (P < .01). Participants in group C showed seropositive rates of 98.9%, 99.9%, 99.5%, 95.5%, 92.8% after the revaccination with GMTs of 6519.6 mIU/ml, 5267.4 mIU/ml, 547.1 mIU/ml, 249.5 mIU/ml, 155.3 mIU/ml, respectively, higher than group A and B (P < .001), except 1 month after the third dose. The 10 μg of HBV vaccine with a 0-1-6-month booster regimen may elicit robust responses and persist for 8 years or longer. Additionally, 1-dose revaccination maybe suitable for children with 1 to < 10 mIU/ml anti-HBs titers.
Definition of Effective Training Sets for Supervised Classification of Remote Sensing Images by a Novel Cost-Sensitive Active Learning Method

B. Demir,Luca Minello,L. Bruzzone

DOI: https://doi.org/10.1109/TGRS.2013.2249522

IF: 8.2

2014-02-01

IEEE Transactions on Geoscience and Remote Sensing

Abstract:This paper proposes a novel cost-sensitive active learning (CSAL) method to the definition of reliable training sets for the classification of remote sensing images with support vector machines. Unlike standard active learning (AL) methods, the proposed CSAL method redefines AL by assuming that the labeling cost of samples during ground survey is not identical, but depends on both the samples accessibility and the traveling time to the considered locations. The proposed CSAL method selects the most informative samples on the basis of three criteria: 1) uncertainty; 2) diversity; and 3) labeling cost. The labeling cost of the samples is modeled by a novel cost function that exploits ancillary data such as the road network map and the digital elevation model of the considered area. In the proposed method, the three criteria are applied in two consecutive steps. In the first step, the most uncertain samples are selected, whereas in the second step the uncertain samples that are diverse and have low labeling cost are chosen. In order to select the uncertain samples that optimize the diversity and cost criteria, we propose two different optimization algorithms. The first algorithm is defined on the basis of a sequential forward selection optimization strategy, whereas the second one relies on a genetic algorithm. Experimental results show the effectiveness of the proposed CSAL method compared to standard AL methods that neglect the labeling cost.
Response to hepatitis B vaccination in patients with liver cirrhosis

Ioanna Aggeletopoulou,Panagiota Davoulou,Christos Konstantakis,Konstantinos Thomopoulos,Christos Triantos

DOI: https://doi.org/10.1002/rmv.1942

2017-09-14

Reviews in Medical Virology

Abstract:Hepatitis B vaccination is strongly recommended for all infants and children but also for adults who are at risk of HBV infection. Attempts to immunize patients with liver cirrhosis have been proven relatively ineffective, and several strategies have already been used to improve the immune response in this group. The primary aim of this review is to examine, discuss, and summarize the immunogenicity of hepatitis B vaccination in patients with liver cirrhosis. MEDLINE search identified 11 studies (n = 961). The dose of the vaccine and the schedule of the vaccination varied. The response rates to the HBV vaccination ranged from 16% to 87% among patients with cirrhosis regardless of the number and vaccine dose. In particular, patients who received the standard dose of vaccination achieved seroprotection rates ranged from 16% to 79% (mean response rate 38%) and those who received a double dose achieved relatively better seroprotection rates (range: 26%-87%; mean response rate 53%). The overall mean response rate to the HBV vaccination was 47%. In conclusion, cirrhotic patients achieve lower seroprotection rates after the completion of HBV vaccination series. Several strategies have tried to improve the immunogenicity; however, there is a great need for additional studies to further explore (1) the immune response in relation to poor vaccination responsiveness confounding factors, (2) novel strategies to improve immunogenicity, and (3) the immune mechanism underlying the differences in response rates to HBV vaccination.

virology
Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

Patricia Richi,Oriol Alonso,María Dolores Martín,Laura González-Hombrado,Teresa Navío,Marina Salido,Jesús Llorente,Cristina Andreu-Vázquez,Cristina García-Fernández,Ana Jiménez-Diaz,Leticia Lojo,Laura Cebrián,Israel Thuissard-Vasallo,María José Martínez de Aramayona,Tatiana Cobo,Marta García-Castro,Patricia Castro,Mónica Fernández-Castro,Óscar Illera,Martina Steiner,Santiago Muñoz-Fernández

DOI: https://doi.org/10.1007/s10067-020-05042-2

2020-04-04

Clinical Rheumatology

Abstract:To evaluate the response to hepatitis B virus (HBV) vaccine in patients on biological therapy. Adults with autoimmune inflammatory diseases on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included. Hepatitis B surface antibody (anti-HBs) was measured by ELISA before and after vaccination. Seroconversion was considered when an anti-HBs titer > 10 mIU/mL was achieved. The effect of treatment on the immunoprotective state was studied. The response was compared with that obtained in patients on synthetic disease modifying anti-rheumatic drugs (DMARDs) and healthy controls. A total of 187 patients on biologicals, 48 on synthetic DMARDs, and 49 on healthy controls were analyzed. More than 80% of patients on biologics responded to the vaccine but required more boosters and second vaccine series. Patients who achieved seroconversion were younger than those who did not (47.10 ± 12.99 vs. 53.18 ± 10.54 years, p = 0.012). Being on etanercept or golimumab was associated with seroconversion, while being on rituximab was not. Seroconversion was achieved in 93.75% of patients on synthetic DMARDs and 97.96% of healthy controls. The seroconversion rate in the biologics group was lower than in the synthetic DMARD group (p = 0.043) and tended to be lower than in the healthy group (p = 0.056). In patients on biological therapy, a high rate of HBV vaccine response can be achieved when a complete vaccination schedule is administered. Vaccination while not on biological agents reduces the requirement for boosters and revaccination.

rheumatology
Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease

Panagiotis Markopoulos,Konstantinos Karmiris,Ioannis Dimas,Evangelos Voudoukis,Spyridon Siakavellas,Georgios Axiaris,Eirini Zacharopoulou,Evanthia Zampeli,Eftychia Tsironi,Maria Tzouvala,Georgios Papatheodoridis,Georgios Bamias

DOI: https://doi.org/10.1093/ibd/izae173

2024-08-05

Abstract:Background: Patients with inflammatory bowel disease (IBD) exhibit an increased risk for acquiring hepatitis B virus (HBV), thus they should be vaccinated preferably, if not already infected or immunized. We assessed the efficacy of HBV vaccination in IBD patients and impact of different factors on the immune response. We also evaluated the success rate of 2 different revaccination strategies in the nonresponders. Methods: This was a retrospective observational cohort study carried out in 5 tertiary centers. All patients were tested for hepatitis B surface antigen, antibodies against hepatitis B surface antigen (anti-HBs), and antibodies against hepatitis B core antigen. Patients tested negative and underwent the standard schedule with 20 µg at 0, 1, and 6 months. Nonresponders (anti-HBs <10 IU/L) were offered a revaccination scheme with either 3 doses of 40 µg at 0, 1, and 6 months or an accelerated scheme with 20 µg at 0, 1, and 2 months. Results: A total of 409 patients were included, and 273 (66.7%) of those (females: 49.5%; Crohn's disease [CD]: 56.7%) responded to baseline vaccination. A total of 189 (69.2%) of 273 (females: 48.1%; CD: 60.3%) developed anti-HBs >100 IU/L. Body mass index <30 kg/m2 (P = .017) was positively associated, while diagnosis of CD (P = .013), extensive UC (P <.0001), extraintestinal manifestations (P = .001), and treatment with immunomodulators/anti-tumor necrosis factor (P < .00) negatively affected the response. Revaccination was offered to 103 patients, and 58.3% of them achieved anti-HBs >10 IU/L. Both revaccination strategies were equally effective. Conclusions: IBD patients demonstrate lower response to HBV vaccination compared with the general population. Age, body mass index, type, disease activity, and immunosuppression negatively affect the response. Half of nonresponders may benefit from an enhanced revaccination attempt.
The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Zikang Wu,Jun Yao,Hongdan Bao,Yongdi Chen,Shunshun Lu,Jing Li,Linna Yang,Zhenggang Jiang,Jingjing Ren,Kai-Jin Xu,Bing Ruan,Shi-Gui Yang,Tian-Sheng Xie,Qian Li

DOI: https://doi.org/10.1080/21645515.2018.1426419

2018-01-01

Human Vaccines & Immunotherapeutics

Abstract:The aim of this study was to evaluate changes in hepatitis B surface antibody titers (anti-HBs) after booster vaccinations in children aged 5-15 y and to provide suitable immunization strategies. A total of 2208 children were initially enrolled in screening, and 559 children were finally included. The participants were divided into 2 groups according to their pre-booster anti-HBs levels: Group I, <10mIU/ml and Group II, 10mIU/ml. Group I was administered 3 doses of booster hepatitis B vaccine (0-1-6months, 10g), and Group II was administered 1 dose of booster hepatitis B vaccine (10g). The antibody titer changes were examined at 4 time points: 1month after dose 1 and dose 3, and 1year and 5years after dose 3. The protective seroconversion rates at those points were 95.65%, 99.67%, 97.59% and 91.05% (p < 0.001), respectively, in Group I, and 100.00%, 99.87%, 99.66% and 98.21% ((2) = 6.04, p = 0.11), respectively, in Group II. The GMT in subjects aged 5-9y were higher than that in subjects aged 10-15y in both Group I and Group II at 1month after dose 1, but no difference was observed at the other three time points. This study demonstrates that booster vaccination has a good medium-term effect. A booster dose for subjects with protective antibodies is not necessary but effective, and 3 doses of hepatitis B vaccination are recommended for those who have lost immunological memory. Receiving booster immunization at the age of10-15years may be more appropriate for individuals living in HBV high epidemic areas
Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Shunshun Lu,Jingjing Ren,Qian Li,Zhenggang Jiang,Yongdi Chen,Kaijin Xu,Bing Ruan,Shigui Yang,Tiansheng Xie,Linna Yang,Jing Li,Jun Yao

DOI: https://doi.org/10.1080/21645515.2016.1260794

2017-01-01

Human Vaccines & Immunotherapeutics

Abstract:This study was aimed at evaluating the changes of hepatitis B surface antibody (anti-HBs) titer after booster vaccinations in 5-15-year-old children with negative antibodies (<10 mIU/mL). 225 subjects (mean age, 9.28 +/- 2.95 years) included in the study consisted of 123 males and 102 females, with a complete hepatitis B vaccination during infancy. The participants were divided into 3 groups according to their pre-booster anti-HBs level: Group I, <0.1 mIU/mL; Group II, 0.1 to <1.0 mIU/mL; Group III, 1.0 to <10.0 mIU/mL. All the participants were administered 3 doses of booster hepatitis B vaccination (0-1-6 month, 20 mu g), and changes in the levels of antibodies were examined at 4 time-points (one month after the first and the third dose, one year and 5years after the third dose). The seroprotective rate (defined as anti-HBs 10.0 mIU/mL) among 225 subjects at the 4 time-points were 93.8%, 100%, 83.6% and 73.4%, respectively ((2) = 90.29, p < 0.05). The seroprotective rate (10 mIU/mL) and anti-HBs geometric mean titer (GMT) in Group III were always higher than those in the other 2 groups (all p < 0.05). The immune effect of a 3 -dose booster revaccination is good, and the booster-induced immune response was correlated with the pre-booster titer level, and 1.0 mIU/mL ensuring a robust positive response, whereas titers below this value may indicate the need for a course of booster vaccination.
Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Guo-Cai Lv,Jin-Mei Yao,Yi-Da Yang,Lin Zheng,Ji-Fang Sheng,Yu Chen,Lan-Juan Li

DOI: https://doi.org/10.3748/wjg.v19.i22.3481

2013-01-01

Abstract:AIM:To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients.METHODS:One hundred and forty patients with HBV-related decompensated cirrhosis were recruited, 70 patients were treated with combined LAM and ADV de novo therapy, and the other 70 patients were treated with LAM alone as controls. The follow-up period was 144 wk. All patients with LAM resistance were shifted to ADV.RESULTS:The percentage of HBV-related decompensated cirrhosis patients with undetectable HBV DNA in de novo combination group was 51.6% (33/64), 84.2% (48/57), and 92.3% (49/53) by weeks 48, 96, and 144, respectively. In monotherapy group, HBV DNA negativity rate was 46.1% (30/65), 56.1% (32/57), and 39.2% (20/51) by weeks 48, 96 and 144, respectively. There was a significant difference between the two groups by weeks 96 and 144 (P = 0.012 and 0.001). The hepatitis B e antigen seroconversion rate was 28.1% (9/32), 40.0% (12/30), and 53.6% (15/28) in the combination group by weeks 48, 96 and 144, respectively, and 24.2% (8/33), 31.0% (9/29), and 37.0% (10/27) by weeks 48, 96 and 144, respectively, in monotherapy group. A total of 68.6% (44/64), 84.2% (48/57), and 92.5% (49/53) patients achieved alanine aminotransferase (ALT) normalization by weeks 48, 96 and 144, respectively in the combination group. In monotherpy group, the ALT normalization rate was 64.6% (42/65) by week 48, 73.7% (42/57) by week 96, and 80.4% (41/51) by week 144. No patients in the combination group exhibited detectable resistance for at least 144 wk. The cumulative resistance rate in monotherapy group at weeks 48, 96, and 144 was 20.0%, 36.8%, and 56.9%. Both combination group and monotherapy group demonstrated an improvement in Child-Turcotte Pugh and Model for End-Stage Liver Disease scores at weeks 48, 96, and 144. All patients tolerated both combination and monotherapy. The ceratinine levels and glomerular filtration rate remained normal in all patients during the follow-up period.CONCLUSION:In HBV-related decompensated liver cirrhosis patients, the combined de novo LAM and ADV therapy is more efficacious and safer compared to LAM alone.
Granulocyte Colony Stimulating Factor Adjuvant Role on the Immunological Response to Hepatitis B Vaccine in Patients With Cirrhosis: A Double Blind Randomized Placebo Controlled Trial

Kamran Bagheri Lankarani,Mozaffar Talebzadeh,Ahad Eshraghian,Seyed Ali Malek-Hosseini

DOI: https://doi.org/10.5812/hepatmon.15447

2014-05-07

Hepatitis Monthly

Abstract:BACKGROUND: Patients with liver cirrhosis have usually poor antibody response to hepatitis B virus (HBV) vaccination.OBJECTIVES: This study aimed to investigate the effect of granulocyte colony stimulating factor (G-CSF) on increasing antibody titers, after HBV vaccination, in patients with liver cirrhosis waiting for transplantation.PATIENTS AND METHODS: From 56 patients with cirrhosis, 28 patients were allocated to receive double dose HBV vaccine (40 μgr) plus G-CSF and 28 patients were allocated to receive double dose HBV vaccine (40 μgr) plus placebo. Injections were performed on weeks 0, 4 and 8 and the blood samples were obtained one month after each vaccination session.RESULTS: There was no statistically significant difference between anti-HBV antibody titers in patients receiving double dose HBV vaccination plus G-CSF and patients receiving double dose HBV vaccination plus placebo, after first, second or third vaccination rounds (P > 0.05). Although the adjuvant G-CSF injection did not cause significant increased antibody titers in our patients compared to the placebo group, the increase in antibody titers following vaccination, happened faster in this group, compared to the placebo group.CONCLUSIONS: The present study showed that G-CSF is not superior to placebo in production of protective antibody titers after HBV vaccination but could result in a more rapid antibody response, compared to the placebo.

gastroenterology & hepatology
The Response of Hepatitis B Vaccination on Seronegative Adults with Different Vaccination Schedules.

Jun Yao,Jing Li,Yongdi Chen,Huan Shan,Xue-wei Dai,Lin-na Yang,Zheng-gang Jiang,Jing-jing Ren,Kai-jin Xu,Bing Ruan,Shi-gui Yang,Bing Wang,Tian-sheng Xie,Qian Li

DOI: https://doi.org/10.4161/21645515.2014.985500

2015-01-01

Human Vaccines & Immunotherapeutics

Abstract:The purpose of this study was to compare the response of hepatitis B vaccination with different vaccination schedules among seronegative adults, and to provide suitable vaccination schedules for floating and fixed population. The study included adults aged 20 to 39 y without prior history of vaccination with hepatitis B vaccine. The serum samples were collected and tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) levels. Out of all, 686 adults who were negative for anti-HBs, anti-HBc and HBsAg were vaccinated with 10 ug hepatitis B vaccine at 0, 1 and 3, 6 or 12 month schedules, and their antibody titers were monitored. The rates of completion of the vaccination in floating and fixed population were 90.4% and 94.1% respectively (p = 0.061). The anti-HBs positive rates in adults vaccinated at 0, 1 and 3 ,6 or12 month were 83.9%, 88.2% and 94.2% respectively (P = 0.0003). The corresponding geometric mean titers (GMTs) were 61.19 (95%CI:47.10-81.23) mIU/mL, 214.04(95%CI:157.14-291.61) mIU/mL and 345.78(95%CI:251.25-475.77) mIU/mL, respectively (P < 0.0001). Vaccination of hepatitis B with both 0-1-6 and 0-1-12 month schedules in adults result in better level of immune responses. Also, a longer vaccination schedule (0-1-12 month) may be more suitable for floating population and 0-1-6 month schedule is recommended for the fixed population.
Results of a Phase III Clinical Trial with an HBsAg-HBIG Immunogenic Complex Therapeutic Vaccine for Chronic Hepatitis B Patients: Experiences and Findings.

Dao-Zhen Xu,Xuan-Yi Wang,Xin-Liang Shen,Guo-Zhong Gong,Hong Ren,Li-Min Guo,Ai-Min Sun,Min Xu,Lan-Juan Li,Xin-Hui Guo,Zhen,Hui-Fen Wang,Huan-Yu Gong,Cheng Xu,Nan Jiang,Chen Pan,Zuo-Jiong Gong,Ji-Ming Zhang,Jia Shang,Jie Xu,Qing Xie,Tie-Feng Wu,Wen-Xiang Huang,Yong-Guo Li,Jing Xu,Zheng-Hong Yuan,Bin Wang,Kai Zhao,Yu-Mei Wen,Yic Efficacy Trial Study Team

DOI: https://doi.org/10.1016/j.jhep.2013.05.003

IF: 25.7

2013-01-01

Journal of Hepatology

Abstract:Background & Aims: Even though various experimental therapeutic approaches for chronic hepatitis B infection have been reported, few of them have been verified by clinical trials. We have developed an antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic vaccine candidate with alum as adjuvant (YIC), aimed at breaking immune tolerance to HBV by modulating viral antigen processing and presentation. A double-blind, placebo-controlled, phase II B clinical trial of YIC has been reported previously, and herein we present the results of the phase III clinical trial of 450 patients.Methods: Twelve doses of either YIC or alum alone as placebo were administered randomly to 450 CHB patients and they were followed for 24 weeks after the completion of immunization. The primary end point was HBeAg seroconversion, and the secondary end points were decrease in viral load, improvement of liver function, and histology.Results: In contrast to the previous phase II B trial using six doses of YIC and alum as placebo, six more injections of YIC or alum resulted in a decrease of the HBeAg seroconversion rate from 21.8% to 14.0% in the YIC group, but an increase from 9% to 21.9% in the alum group. Decrease in serum HBV DNA and normalization of liver function were similar in both groups (p > 0.05).Conclusions: Overstimulation with YIC did not increase but decreased its efficacy due to immune fatigue in hosts. An appropriate immunization protocol should be explored and is crucial for therapeutic vaccination. Multiple injections of alum alone could have stimulated potent inflammatory and innate immune responses contributing to its therapeutic efficacy, and needs further investigation. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.
Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients

Dao-Zhen Xu,Kai Zhao,Li-Min Guo,Xin-Yue Chen,Hui-Fen Wang,Ji-Ming Zhang,Qin Xie,Hong Ren,Wen-Xiang Wang,Lan-Juan Li,Min Xu,Pei Liu,Jun-Qi Niu,Xue-Fan Bai,Xin-Liang Shen,Zheng-Hong Yuan,Xuan-Yi Wang,Yu-Mei Wen

DOI: https://doi.org/10.1371/journal.pone.0002565

IF: 3.7

2008-01-01

PLoS ONE

Abstract:Background: The safety of the immune complexes composed of yeast-derived hepatitis B surface antigen (HBsAg) and antibodies (abbreviated as YIC) among healthy adults and chronic hepatitis B patients has been proved in phase I and phase IIa trial. A larger number of patients for study of dosage and efficacy are therefore needed.Methods and Principal Findings: Two hundred forty two HBeAg-positive chronic hepatitis B patients were immunized with six injections of either 30 mg YIC, 60 mg of YIC or alum adjuvant as placebo at four-week intervals under code. HBV markers and HBV DNA were monitored during immunization and 24 weeks after the completion of immunization. The primary endpoint was defined as loss of HBeAg, or presence of anti-HBe antibody or suppression of HBV DNA, while the secondary endpoint was both HBeAg seroconversion and suppression of HBV DNA. Statistical significance was not reached in primary endpoints four weeks after the end of treatment among three groups, however, at the end of follow-up, HBeAg seroconversion rate was 21.8%(17/78) and 9% (7/78) in the 60 mg YIC and placebo groups respectively (p = 0.03), with 95% confidence intervals at 1.5% to 24.1%. Using generalized estimating equations (GEEs) model, a significant difference of group effects was found between 60 mg YIC and the placebo groups in terms of the primary endpoint. Eleven serious adverse events occurred, which were 5.1%, 3.6%, and 5.0% in the placebo, 30 mg YIC and 60 mg YIC groups respectively (p > 0.05).Conclusions: Though statistical differences in the preset primary and secondary endpoints among the three groups were not reached, a late and promising HBeAg seroconversion effect was shown in the 60 mg YIC immunized regimen. By increasing the number of patients and injections, the therapeutic efficacy of YIC in chronic hepatitis B patients will be further evaluated.
Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults

Vania Giacomet,Michela Masetti,Pilar Nannini,Federica Forlanini,Mario Clerici,Gian Vincenzo Zuccotti,Daria Trabattoni

DOI: https://doi.org/10.1371/journal.pone.0192638

IF: 3.7

2018-02-14

PLoS ONE

Abstract:OBJECTIVE: HBV vaccine induces protective antibodies only in 23-56% of HIV-infected children. The aim of our study is to evaluate the immunologic effects of a booster dose of HBV vaccine in HIV-infected youth.DESIGN: 53 young HIV-infected patients in whom HBV vaccination did not elicit protective Ab titers were enrolled. All patients were on ART with optimal immunological and viral response.METHOD: All patients received a booster dose of HBV vaccine (HBVAXPRO 10 μg i.m.). HBV-specific Ab titer, viral load and CD4+ T cells were measured at baseline (T0), T1, T6 and T12 months. In a subgroup of 16 patients HBV-specific cell mediated immune responses were evaluated at baseline, at T1 and T6.RESULTS: The booster dose induced seroconversion in 51% of patients at T1, 57% at T6, and49% at T12; seroconversion rate was significantly correlated with CD4+T cells at T0 and to the CD4 nadir. The booster dose induced HBV-specific cell mediated immunity at T6 mainly in Responders (Rs): Effector Memory CD8+T cells, HBV-specific TNFα-, IFNγ-, granzyme secreting CD8+ T cells and IL2-secreting CD4+ T cells were significantly increased in Rs compared to T0. In Non Responders (NRs), HBV-specific IL2-secreting CD4+ T cells, Central and Effector Memory CD8+ T cells were the only parameters modified at T6.CONCLUSIONS: Seroconversion induced by a booster dose of vaccine correlates with the development of T cell immunological memory in HIV-infected patients who did not respond to the standard immunization. Alternate immunization schedules need to be considered in NRs.

multidisciplinary sciences
Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies

Fernández-Prada María,Brandy-García Ana María,Rodríguez-Fonseca Omar Darío,Alonso-Penanes Paula,Latorre-Royán Josep Vicent,Fernández-Peón Inés,Fernández-González Lucía,Fernández-Rodríguez Germán,Fernández-Noval Federico,Huerta-González Ismael

DOI: https://doi.org/10.1016/j.vaccine.2022.12.009

IF: 4.169

2023-01-16

Vaccine

Abstract:Background: Hepatitis B vaccination is necessary for patients with biologic therapies because of the immunomodulatory effect of these drugs. Due to the elevated use of these therapies in the latest years, the research for new vaccination regimens and the improvement of the current ones is essential. New adjuvants like AS04C might be a potential strategy to improve immune response. Hepatitis B vaccine adjuvanted with AS04C has not been studied in this population before. We analyzed the immunogenicity of an adjuvanted hepatitis B vaccine in patients with biologic therapies. Variables that might affect vaccine response were also evaluated. Methods: Analytic observational retrospective cohort study performed between January 2016 and September 2018. 301 patients under biological treatment aged from 18 years were included. Patients received 4 doses of hepatitis B adjuvanted vaccine (Fendrix®) in a 0-1-2-6 month immunization schedule. Several sociodemographic, clinical and pharmacological variables were evaluated. The outcome variable was measured as the antibody titers (anti-HBs). The geometric mean of titers (GMT) as a measure for the central tendency was calculated from these values. Results: The immunization schedule of the hepatitis B vaccine adjuvanted with AS04C demonstrated high levels of seroconversion with 82.1 % (95 % CI, 77.6-86.6) of vaccinated patients seroconverting after primary vaccination and achieving 89.0 % (95 % IC, 85.3-92.7) after the booster doses for non-responders. The use of corticosteroid therapy and high doses of them, age over 60 years and the main diagnosis were associated with lower seroconversion rates and lower anti-HBs titers. Conclusions: The hepatitis B vaccine adjuvanted with AS04C (Fendrix®) produces an adequate immune response in patients with autoimmune diseases and immunosuppressive and/or immunomodulating therapies. This immunization schedule is proposed as a very suitable and adapted option for the protection of patients with autoimmune diseases under active biological therapies.
Revaccination of Non- and Low- Responders after a Standard Three Dose Hepatitis B Vaccine Schedule

Ke Han,Xiaoping Shao,Huizhen Zheng,Chenggang Wu,Jianqiong Zhu,Xiaoli Zheng,Yonghui Zhang

DOI: https://doi.org/10.4161/hv.21818

2012-01-01

Human Vaccines & Immunotherapeutics

Abstract:Background: Guangdong province of China is HBV high endemicity and 1.6 million neonates are administrated 5 mu g yeast recombinant anti-HBV vaccine each year. But few studies are performed to evaluate the immunogenicity and revaccination effect on non-and low-responders.Results: Of 1,814 subjects, 3.1% were non-responders (anti-HBs titer < 10 mIUml(-1)) and 28.9% were low-responders (anti-HBs >= 10 mIUml(-1) and < 100 mIUml(-1)). Low birth weight (LBW) was a risk factor for non- and low-responders (RR = 1.6, 95% CI = 1.2-2.0). After revaccination, of the 34 non-responders, 14.7% became low-responders and 85.3% became responders. Of the 74 low-responders, 21.6% remained at the same level and 78.4% shifted into responder category.Methods: A total of 2,199 children were administered intramuscularly with 5 mu g vaccine at 0, 1 and 6 mo after birth. A 3 ml blood sample was drawn from each infant 1 mo after the third dose for determination of anti-HBs level. Three additional doses (10 mu g each) were given to non-and low-responders.Conclusions: Based on the lower responding rate after the primary immunization cycle and the higher responding rate after the additional cycle, measurement of anti-HBs level should be considered for people who had been immunized with three-dose 5 mu g HB vaccine in Guangdong, especially for specific populations including LBW infants, healthcare workers, and patients with immunodeficiency disorders. An amount of 10 mu g vaccine should be revaccinated to any non- and low-responders to provide adequate seroprotection.
Utility of a Third Heplisav-B Dose in Patients with Inflammatory Bowel Disease without Immunity Following Two-Dose Heplisav-B Vaccination

Christian Karime,Cecily N. Black,Pedro Cortes,Joshua Y. Kwon,Freddy Caldera,Shenna K. Crosby,Michael F. Picco,Jami A. Kinnucan,Jana G. Hashash,Francis A. Farraye

DOI: https://doi.org/10.14309/ajg.0000000000002863

2024-05-09

The American Journal of Gastroenterology

Abstract:Objectives: Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory bowel disease (IBD). Although the two-dose Heplisav-B vaccine has proven effective, more than 20% of patients with IBD do not seroconvert. We prospectively evaluated the effectiveness of a third Heplisav-B dose in patients with IBD lacking HBV immunity despite two-dose vaccination. Methods: Adults with IBD who had received two-dose Heplisav-B vaccination between 2018-2023 were identified. Seroconversion was defined as hepatitis B surface antibody (HBsAb) >10 IU/L measured at >4 weeks following vaccination. Patients who did not seroconvert were prospectively offered a third Heplisav-B dose, followed by repeat HBsAb measurement. Demographic, clinical, medication, and vaccination data was compared between those who did and did not seroconvert. Results: Of 192 patients identified, 71.9% (138/192) seroconverted following two-dose Heplisav-B vaccination. The 54 patients (28.1%) who did not seroconvert were more likely to be male, have diabetes, chronic kidney disease, or elevated Charlson Comorbidity Index. Of the 54 patients, 30 (55.6%) elected to receive a third Heplisav-B dose, with 56.7% (17/30) achieving seroconversion (median HBsAb titer 376 IU/L, IQR 47-1000 IU/L) despite a median inter-vaccination time of 416 days (IQR 90.8-667.8). No differences were noted between patients who did versus did not seroconvert following third dose vaccination. Conclusion: In patients with IBD lacking HBV immunity despite two-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary two-dose vaccination.

gastroenterology & hepatology
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

Gautam Mehta,Antonio Riva,Maria Pilar Ballester,Eva Uson,Montserrat Pujadas,Ângela Carvalho-Gomes,Ivan Sahuco,Ariadna Bono,Federico D'Amico,Raffaela Viganò,Elena Diago,Beatriz Tormo Lanseros,Elvira Inglese,Dani Martinez Vazquez,Rajni Sharma,Hio Lam Phoebe Tsou,Nicola Harris,Annelotte Broekhoven,Marjolein Kikkert,Shessy P Torres Morales,Sebenzile K Myeni,Mar Riveiro-Barciela,Adriana Palom,Nicola Zeni,Alessandra Brocca,Annarosa Cussigh,Sara Cmet,Desamparados Escudero-García,Matteo Stocco,Leonardo Antonio Natola,Donatella Ieluzzi,Veronica Paon,Angelo Sangiovanni,Elisa Farina,Clara di Benedetto,Yolanda Sánchez-Torrijos,Ana Lucena-Varela,Eva Román,Elisabet Sánchez,Rubén Sánchez-Aldehuelo,Julia López-Cardona,Itzel Canas-Perez,Christine Eastgate,Dhaarica Jeyanesan,Alejandro Esquivel Morocho,Simone Di Cola,Lucia Lapenna,Giacomo Zaccherini,Deborah Bongiovanni,Paola Zanaga,Katia Sayaf,Sabir Hossain,Javier Crespo,Mercedes Robles-Díaz,Antonio Madejón,Helena Degroote,Javier Fernández,Marko Korenjak,Xavier Verhelst,Javier García-Samaniego,Raúl J Andrade,Paula Iruzubieta,Gavin Wright,Paolo Caraceni,Manuela Merli,Vishal C Patel,Amir Gander,Agustín Albillos,Germán Soriano,Maria Francesca Donato,David Sacerdoti,Pierluigi Toniutto,Maria Buti,Christophe Duvoux,Paolo Antonio Grossi,Thomas Berg,Wojciech G Polak,Massimo Puoti,Anna Bosch-Comas,Luca Belli,Patrizia Burra,Francesco Paolo Russo,Minneke Coenraad,José Luis Calleja,Giovanni Perricone,Marina Berenguer,Joan Claria,Richard Moreau,Vicente Arroyo,Paolo Angeli,Cristina Sánchez,Javier Ampuero,Salvatore Piano,Shilpa Chokshi,Rajiv Jalan,COBALT Consortium

DOI: https://doi.org/10.1097/HC9.0000000000000273

2023-10-18

Abstract:Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection. Methods: COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver disease (AILD) (n = 120; 77% mRNA and 23% viral vaccine), post-liver transplant (LT) (n = 146; 96% mRNA and 3% viral vaccine), and healthy controls (n = 51; 72% mRNA, 24% viral and 4% heterologous combination). Serological end points were measured, and data regarding breakthrough SARS-CoV-2 infection were collected. Results: After adjusting by age, sex, and time of sample collection, anti-Spike IgG levels were the lowest in post-LT patients compared to cirrhosis (p < 0.0001), AILD (p < 0.0001), and control (p = 0.002). Factors predicting reduced responses included older age, Child-Turcotte-Pugh B/C, and elevated IL-6 in cirrhosis; non-mRNA vaccine in AILD; and coronary artery disease, use of mycophenolate and dysregulated B-call activating factor, and lymphotoxin-α levels in LT. Incident infection occurred in 6.6%, 10.6%, 7.4%, and 15.6% of cirrhosis, AILD, post-LT, and control, respectively. The only independent factor predicting infection in cirrhosis was low albumin level. Conclusions: LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level.
Immunogenicity and Safety of a Booster COVID-19 Vaccination in Patients with Chronic Liver Disease:A Multicenter Study

Jitao Wang,Jingwen Ai,Huiling Xiang,Yanliang Zhang,Zhiyun Hou,Qiran Zhang,Jiaojian Lv,Shubo Chen,Chuan Liu,Qianqian Li,Jing Liang,Faren Xie,Shujun Jiang,Nina Zhang,Aiguo Zhang,Xiaolin Lan,Xuying Zhang,Jinlong Li,Dengxiang Liu,Wenchuan Wang,Wei Rao,Zhang Qun,Qiuju Tian,Xiaolong Qi,Wenhong Zhang

DOI: https://doi.org/10.1002/poh2.57

2023-01-01

Abstract:Aim: Patients with chronic liver disease (CLD), especially cirrhosis, are at a high risk of severe illness or death from coronavirus disease-2019 (COVID-19) and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. This study aimed to evaluate the safety and immunogenicity of the COVID-19 booster vaccination in patients with CLD. Methods: The study protocol was prospectively registered at (No. NCT05204602) after approval by the Ethics Committee. Adult participants with CLD were enrolled in this multicenter prospective study. They completed two doses of the inactivated COVID-19 vaccine and received booster doses at least 6 months later. Adverse reactions were recorded within 14 days after the booster dose. Serum samples of the enrolled patients were collected before and after booster vaccination and tested for SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin G and neutralizing antibodies. The chi-squared or Fisher's exact test was used to compare categorical data, and the Mann-Whitney U test was used to compare continuous variables. Two-sided p < 0.05 were considered statistically significant. Results: In total, 63 patients were enrolled from four hospitals in China, including 29 patients with cirrhosis. The median age of all patients was 55 years, and 61.9% (39/63) were male. The vaccines were well tolerated; most adverse reactions were mild and transient, and injection site pain (6.4%; 4/63) and fatigue (3.2%, 2/63) were the most frequent local and systemic adverse events. Following the booster vaccination, our results showed that in the whole cohort, the levels and positive rates of anti-RBD IgG and neutralizing antibodies were significantly higher than baseline levels (all p < 0.05). Conclusions: The inactivated COVID-19 booster vaccine was safe and significantly increased antibody levels and positivity rates following standard vaccination regimens in patients with CLD, especially those with cirrhosis.

Detection and quantitation of circulating immune complexes in arterial blood of patients with rheumatic disease.

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Efficacy of an accelerated double‐dose hepatitis B vaccine regimen in patients with cirrhosis

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Definition of Effective Training Sets for Supervised Classification of Remote Sensing Images by a Novel Cost-Sensitive Active Learning Method

Response to hepatitis B vaccination in patients with liver cirrhosis

Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Granulocyte Colony Stimulating Factor Adjuvant Role on the Immunological Response to Hepatitis B Vaccine in Patients With Cirrhosis: A Double Blind Randomized Placebo Controlled Trial

The Response of Hepatitis B Vaccination on Seronegative Adults with Different Vaccination Schedules.

Results of a Phase III Clinical Trial with an HBsAg-HBIG Immunogenic Complex Therapeutic Vaccine for Chronic Hepatitis B Patients: Experiences and Findings.

Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients

Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults

Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies

Revaccination of Non- and Low- Responders after a Standard Three Dose Hepatitis B Vaccine Schedule

Utility of a Third Heplisav-B Dose in Patients with Inflammatory Bowel Disease without Immunity Following Two-Dose Heplisav-B Vaccination

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

Immunogenicity and Safety of a Booster COVID-19 Vaccination in Patients with Chronic Liver Disease:A Multicenter Study